ERRATUM|
March 30, 2023
Heiblig M, Ferrada MA, Koster MT, et al. Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study. Blood. 2022;140(8):927-931.
Blood (2023) 141 (13): 1647.
Connected Content
Citation
Heiblig M, Ferrada MA, Koster MT, et al. Ruxolitinib is more effective than other JAK inhibitors to treat VEXAS syndrome: a retrospective multicenter study. Blood. 2022;140(8):927-931.. Blood 2023; 141 (13): 1647. doi: https://doi.org/10.1182/blood.2023019982
Download citation file: